Horizon Therapeutics Plc (HZNP):財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(GDPH243700FSA)
◆英語タイトル:Horizon Therapeutics Plc (HZNP) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH243700FSA
◆発行会社(リサーチ会社):GlobalData
◆発行日:2021年3月
◆ページ数:57
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:Ireland
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Horizon Therapeutics Plc (HZNP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Horizon Therapeutics Plc (Horizon Therapeutics) formerly known as Horizon Pharma plc, is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. Few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo among others. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada and Israel. Horizon Therapeutics is headquartered in Dublin, Leinster, Ireland.

Horizon Therapeutics Plc Key Recent Developments

Mar 24,2021: Horizon Therapeutics launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to sdvance solutions for the rare disease community
Mar 11,2021: Horizon Therapeutics named as one of the Best Workplaces in Ireland
Feb 24,2021: Horizon Therapeutics reports record fourth-quarter and full-year 2020 financial results; Announces full-year 2021 guidance
Feb 22,2021: New survey assessment finds debilitating impact of thyroid eye disease (TED) on quality of life continues well beyond acute disease into chronic phase
Feb 05,2021: Medidata expands partnership with Horizon Therapeutics for trials

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Horizon Therapeutics Plc – Key Facts
Horizon Therapeutics Plc – Key Employees
Horizon Therapeutics Plc – Key Employee Biographies
Horizon Therapeutics Plc – Major Products and Services
Horizon Therapeutics Plc – History
Horizon Therapeutics Plc – Company Statement
Horizon Therapeutics Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Horizon Therapeutics Plc – Business Description
Business Segment: Inflammation
Overview
Performance
Business Segment: Orphan
Overview
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: United States
Performance
Horizon Therapeutics Plc – Corporate Strategy
Horizon Therapeutics Plc – SWOT Analysis
SWOT Analysis – Overview
Horizon Therapeutics Plc – Strengths
Horizon Therapeutics Plc – Weaknesses
Horizon Therapeutics Plc – Opportunities
Horizon Therapeutics Plc – Threats
Horizon Therapeutics Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Horizon Therapeutics Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 24, 2021: Horizon Therapeutics launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to sdvance solutions for the rare disease community
Mar 11, 2021: Horizon Therapeutics named as one of the Best Workplaces in Ireland
Feb 24, 2021: Horizon Therapeutics reports record fourth-quarter and full-year 2020 financial results; Announces full-year 2021 guidance
Feb 22, 2021: New survey assessment finds debilitating impact of thyroid eye disease (TED) on quality of life continues well beyond acute disease into chronic phase
Feb 05, 2021: Medidata expands partnership with Horizon Therapeutics for trials
Feb 04, 2021: Horizon Therapeutics expands Medidata partnership to further enhance clinical trial efficiencies and outcomes
Feb 03, 2021: Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021
Jan 11, 2021: Horizon Therapeutics provides preliminary 2020 financial results, exceeding full-year 2020 net sales and adjusted EBITDA guidance; Provides update on TEPEZZA (teprotumumab-trbw) Supply and new KRYSTEXXA (pegloticase injection) trials
Nov 30, 2020: Horizon Therapeutics donates additional $1.2 million to support COVID-19 relief efforts in Illinois and other impacted U.S. and international communities
Nov 17, 2020: National Association for business resources names Horizon Therapeutics one of the best and brightest companies to work for in the nation
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Horizon Therapeutics Plc, Key Facts
Horizon Therapeutics Plc, Key Employees
Horizon Therapeutics Plc, Key Employee Biographies
Horizon Therapeutics Plc, Major Products and Services
Horizon Therapeutics Plc, History
Horizon Therapeutics Plc, Subsidiaries
Horizon Therapeutics Plc, Key Competitors
Horizon Therapeutics Plc, Ratios based on current share price
Horizon Therapeutics Plc, Annual Ratios
Horizon Therapeutics Plc, Annual Ratios (Cont...1)
Horizon Therapeutics Plc, Annual Ratios (Cont...2)
Horizon Therapeutics Plc, Interim Ratios
Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Horizon Therapeutics Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Horizon Therapeutics Plc (HZNP):財務・戦略的SWOT分析(Horizon Therapeutics Plc (HZNP) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆